RecruitingNCT07118813

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment

400 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

Renal Cell Carcinoma (Kidney Cancer)

Summary

This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using artificial intelligence (AI) and radiomics — the detailed analysis of CT scan images — to predict outcomes in patients with kidney cancer (renal cell carcinoma) treated at Wuhan Union Hospital. Researchers are building AI models to help forecast how patients will respond to treatment and what their prognosis might be. **You may be eligible if...** - You were treated for kidney cancer (renal cell carcinoma) at Wuhan Union Hospital between August 2025 and August 2026 - You are over 18 years old - You had at least one abdominal CT scan before treatment - Your diagnosis was confirmed by tissue biopsy **You may NOT be eligible if...** - Your CT scan images are of poor quality - Your medical records are incomplete or you were lost to follow-up - You have another primary cancer besides kidney cancer - Your kidney cancer diagnosis is unclear from pathology Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07118813

Related Trials

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

NCT075552101 location

Validation of RCC Predicting Model With Emulated-target Trial

NCT071172271 location

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

NCT072346563 locations

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

NCT071975805 locations

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT074851141 location